<sup>1</sup>Clinic for Neurology and Neurorehabilitation, Hospital zum Heiligen Geist, Academic Teaching Hospital of the Heinrich-Heine-University Duesseldorf, Kempen, Germany <sup>2</sup>Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany



## Background

HOSPITAL ZUM HEILIGEN GEIST Kempen

Transcranial Pulse Stimulation (TPS) is a therapy that uses shockwaves for the treatment of Alzheimer's Disease (AD). Recently, our group published short term clinical results after the first treatment cycle of 2 weeks (Cont et al. 2022). Here we analyze 1 year follow-up data.

## Methods

A consecutive number of 25 TPS-treated patients was examined. All patients received 4 Hz TPS of about 6000 pulses of 0.2 mJ/mm<sup>2</sup> (navigated bifrontally, biparietally, bitemporally, and praecuneus) using the Neurolith System (Storz Medical). After the initial treatment cycle of 6 sessions over 2 weeks, patients were planned to receive monthly booster sessions. Cognitive scores were assessed (e.g. ADAS, MMST, MoCA) up to 6 (n = 10) and 12 months (n = 5).






Figure 1.




# 1 year follow-up after Transcranial Pulse Stimulation in Alzheimer's patients

## Lars Wojtecki<sup>1,2</sup> Celine Cont<sup>1,2</sup>, Nathalie Stute<sup>1</sup>, Anastasia Galli<sup>1</sup>, Jessica Schiermeisen<sup>1</sup>

Results										
The treatment was well tolerable with low number of only transient and not severe ADE (From 250 stimulation sessions totally administered: 1.6% drowsiness, 0.8% nausea and headache, and 0.4% jaw pain and										30
										25
earache.)										20
Short-Term R A significant i			oanitive sa	ores v	vas dete	octod				15
in all neuropsy	•		U							10 —
	n	Μ	SD	df	t	р	Cohens d			
MMST- T0	24	16.17	8.042	23	-2.58	.009*	-0			Figure 3. *A
MMST-Post	24	17.29	7.123				.53			improve after
MoCA – TO	24	11.29	6.517	23	-2.24	.018*				transition back
MoCA – Post	24	12.33	6.611				.46			A Pearson col T3, T6, T12)
ADAS – TO	23	28.35	13.217							show stable pe
ADAS - Post	23	26.04	13.227	22	2.58	.009*	.54			Discussion
Long Term Re Long-term dat cognition after every test. 20	a of th	st treatme		nd after	r 3, 6, a	•				These pilot rest to low ADE and These pilot rest can be main assessments controlled trials and subgroups
18										
16		* <i>t(</i> 23) = -2.58, <i>p</i> = .0	009, <i>d</i> = .53.							References
14										Cont, C., Stute, N. Retrospective real Alzheimer's
12		<i>t</i> (23) = -2.24, <i>p</i> = .018	* <i>t</i> (6) = -3.38, <i>p</i> = .0	008, <i>d</i> = 1.28						Alzheimer's p https://doi.org/10.3
10	ТС				Т6	T12				Disclosure
Figure 2. Over		_	-MMSTM	loCA						LW and CC re Storz Medical.





--ADAS

\*A lower scores indicates improvement. Mean scores er the first treatment cycle and 3 months and then ck to baseline at 6 and 12 months.

correlation was calculated for MMST over time (T0, Post, 2) and revealed no significant change, thus patients performance (p = 3.21 with r = .057).

### n / Conclusion

results confirm the recently published results with respect and extent of cognitive improvement as a short-term effect. results show that initial improvement of cognitive functions aintained up to 1 year. More extensive long term need to be performed in larger groups. Prospective als need to show the efficacy of this treatment. More data ps need to be analyzed.

N., Galli, A., Schulte, C., Logmin, K., Trenado, C., & Wojtecki, L. (2022). eal-world pilot data on transcranial pulse stimulation in mild to severe Frontiers 948204. patients. in neurology, .3389/fneur.2022.948204

receive consultancy honoraria and travel payments from